"Ethambutol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863)
Concept/Terms
EMB-Hefa- EMB-Hefa
- EMB Hefa
- Wernigerode Brand of Ethambutol Hydrochloride
- Sanavita Brand of Ethambutol Hydrochloride
Etambutol Llorente- Etambutol Llorente
- Llorente, Etambutol
- Llorente Brand of Ethambutol Hydrochloride
Etibi- Etibi
- Fatol Brand of Ethambutol Hydrochloride
- EMB-Fatol
- EMB Fatol
- ICN Brand of Ethambutol Hydrochloride
Myambutol- Myambutol
- Elan Brand of Ethambutol Hydrochloride
- Miambutol
- Lederle Brand of Ethambutol Hydrochloride
- Riemser Brand of Ethambutol Hydrochloride
- Wyeth Brand of Ethambutol Hydrochloride
- AHP Brand of Ethambutol Hydrochloride
- Genopharm Brand of Ethambutol Hydrochloride
Dexambutol- Dexambutol
- SERB Brand of Ethambutol Hydrochloride
Below are MeSH descriptors whose meaning is more general than "Ethambutol".
Below are MeSH descriptors whose meaning is more specific than "Ethambutol".
This graph shows the total number of publications written about "Ethambutol" by people in Harvard Catalyst Profiles by year, and whether "Ethambutol" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 1 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 2 | 2 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 2 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
Below are the most recent publications written about "Ethambutol" by people in Profiles.
-
The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: A genotypic analysis. Lancet Microbe. 2022 04; 3(4):e265-e273.
-
Risk Factors for Adverse Events in Household Contacts Prescribed Preventive Treatment for Drug-resistant Tuberculosis Exposure. Clin Infect Dis. 2021 05 18; 72(10):1709-1715.
-
BCGitis of the wrist after intravesical BCG therapy: A case report. Hand Surg Rehabil. 2020 12; 39(6):585-587.
-
Multiple tuberculomas in an immunocompetent patient and their diagnostic challenge in a high prevalence country: Case report and literature review. Indian J Tuberc. 2020 Jul; 67(3):286-294.
-
Fisherman's Dilemma: Disseminated Mycobacterium marinum in an Immunosuppressed Patient. Am J Med. 2020 10; 133(10):e549-e551.
-
Identification of new components of the RipC-FtsEX cell separation pathway of Corynebacterineae. PLoS Genet. 2019 08; 15(8):e1008284.
-
Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti. Am J Trop Med Hyg. 2019 02; 100(2):392-398.
-
Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. N Engl J Med. 2018 10 11; 379(15):1403-1415.
-
Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018 04; 6(4):265-275.
-
Short Communication: Mycobacterium avium Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2017 12; 33(12):1202-1204.